NCT06746961View on ClinicalTrials.gov

Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2027

Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
DRUG

QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

5mg/kg , iv, q3w

DRUG

Lenvatinib

8 mg or 12 mg QD via oral capsule

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER

NCT06746961 - Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy | Biotech Hunter | Biotech Hunter